Market experts on what to expect from various sectors in 2014 _ Business Today

Revenue growth is expec ted to be led by growth in

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: om m itm ents of Rs 8,100 c rore over the next five years . Revenue growth is expec ted to be led by growth in infras truc ture & heavy engineering s egm ents . HEALT H CARE "Rev enues are ex pec ted to grow at 10% a y ear till 2014-15" Rak es h Goy al, Senior Vic e Pres ident, Bonanza Portfolio The s ec tor has s hown c ons is tent double-digit growth in the rec ent pas t. However, the US Food and Drug Adm inis tration's dem anding guidelines have hit overs eas s ales . Als o, the governm ent's new pric ing polic y has im pac ted m argins . The dome stic pharma marke t grew about 12% in 2012. Revenues are expec ted to c ontinue growing at 10% a year between 2013-14 and 2014-15. Generic s is em erging as one of the leading s egm ents that will gain as a num ber of drugs go off-patent in the next few years . Governm ent initiatives s uc h as allowing 100% foreign direc t inves tm ent in health and m edic al s ervic es will als o benefit the s ec tor. The governm ent als o plans to inc reas e health expenditure to 2.5% of gros s dom es tic produc t by the end of the 12th Five-Year Plan (201217), whic h will give the s ec tor another big boos t. businesstoday.intoday.in/stor ypr int/201839 12/18 1/2/14 M ar ket exper ts on what to expect fr om var ious sector s in 2014 : Business Today Lupin T arge t price : Rs 950-970 The c om pany's foc us on s trengthening bus ines s in the US and operational effic ienc ies has led to a s us tainable ris e in profits . The c om pany reported 40% growth in net profit for the quarter ended Septem ber 30. Tec hnic ally, the s toc k is in a long-term uptrend, and is likely to hit Rs 950-970 in the m edium term . Biocon T arge t price : Rs 450 The c om pany has im proved its perform anc e over the las t two quarters . It is expanding pres enc e in em erging m arkets . On the c harts als o, the s toc k is s howing s trength in the near to m edium term . W e expec t it to hit Rs 450 in the next s ix to 10 m onths . Sun Pharma T arge t price : Rs 650 The s toc k has perform ed c ons is tently even in advers e m arket c onditions . At pres ent, it is in a c ons olidation phas e. It m ay be bought at c urrent levels with a target of Rs 650 and above in the m edium term . POWER "Gains from falling pric es of im ported c oal are not s us tainable" Daljeet S Kohli, Head of Res earc h,IndiaNiv es h Sec urities The s ec tor has done very poorly over the las t few years as profits s lum ped due to high fuel pric es . But things are c hanging. The businesstoday.intoday.in/stor ypr int/201839 13/18 1/2/14 M ar ket exper ts on what to expect fr om var ious sector s in 2014 : Business Today governm ent is trying to s ort out is s ues related to fuel s upply and los s es of s tate elec tric ity boards . Further, India's per c apita c ons um ption of 704 units a year is m inus c ule c om pared to developed c ountries , whic h indic ates the s ec tor's potential. W e believe that earnings will c ontinue to rem ain volatile due to fuels...
View Full Document

This document was uploaded on 02/06/2014.

Ask a homework question - tutors are online